Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PHIO 
Phio Pharmaceuticals Corp (PHIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/11/2025: PHIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.17% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.22M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 0.89 | 52 Weeks Range 0.97 - 9.79 | Updated Date 11/11/2025 |
52 Weeks Range 0.97 - 9.79 | Updated Date 11/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -56.07% | Return on Equity (TTM) -102.18% |
Valuation
Trailing PE - | Forward PE 0.31 | Enterprise Value 450096 | Price to Sales(TTM) 48.01 |
Enterprise Value 450096 | Price to Sales(TTM) 48.01 | ||
Enterprise Value to Revenue 172.2 | Enterprise Value to EBITDA 0.61 | Shares Outstanding 5726750 | Shares Floating 5676985 |
Shares Outstanding 5726750 | Shares Floating 5676985 | ||
Percent Insiders 7.59 | Percent Institutions 19.98 |
Upturn AI SWOT
Phio Pharmaceuticals Corp
Company Overview
History and Background
Phio Pharmaceuticals Corp. is a biotechnology company focused on developing therapies using self-delivering RNAi (sd-rxRNAu00ae) technology to treat cancers and other diseases. Founded in 1994 as RXi Pharmaceuticals, it changed its name to Phio Pharmaceuticals in 2017 to better reflect its focus. It has evolved from research on gene silencing to clinical development of targeted therapies.
Core Business Areas
- RNAi Therapeutics: Phio develops self-delivering RNAi (sd-rxRNA) therapeutics designed to silence disease-causing genes inside cells, primarily targeting cancers and fibrotic diseases. They are focused on their INTASYL platform.
Leadership and Structure
Dr. Robert Bitterman is the Chairman and CEO. The company has a typical biotech structure with a leadership team overseeing R&D, clinical development, and finance.
Top Products and Market Share
Key Offerings
- INTASYL: INTASYL is Phio's lead clinical candidate targeting solid tumors. It is designed to silence the BRD4 gene. It is in phase 1b trials. Market share data unavailable. Competitors include companies developing similar RNAi or gene silencing therapies, such as Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals, though they often target different genes and diseases.
- PH-762: PH-762 is designed to target TCF7. Preclinical development for immuno-oncology. Market share data unavailable as still in development. Competitors similar to INTASYL.
Market Dynamics
Industry Overview
The RNAi therapeutics market is growing, driven by advancements in delivery technologies and a better understanding of disease biology. It faces challenges related to delivery, off-target effects, and regulatory hurdles.
Positioning
Phio is a small player in the RNAi therapeutics market, focusing on its sd-rxRNA technology. Its competitive advantage lies in its self-delivering approach, potentially simplifying drug delivery and reducing side effects.
Total Addressable Market (TAM)
The global RNAi therapeutics market is projected to reach billions of dollars. Phio is positioning itself to capture a portion of this market by focusing on specific oncology targets. TAM estimates range from $2 billion to $4 billion by 2028 depending on the report.
Upturn SWOT Analysis
Strengths
- Self-delivering RNAi technology (sd-rxRNA)
- Targeted approach to gene silencing
- Potential for simplified drug delivery
- Focus on oncology targets
Weaknesses
- Limited financial resources
- Early stage clinical development
- High risk associated with drug development
- Dependence on key personnel
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new targets
- Positive clinical trial results
- Advancements in RNAi delivery technologies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- ALNY
- ARWR
Competitive Landscape
Phio faces significant competition from larger, well-funded companies in the RNAi therapeutics space. It needs to demonstrate clinical efficacy and safety to differentiate itself.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its developmental stage.
Future Projections: Future growth depends on clinical trial success and potential partnerships. Analyst estimates are difficult to obtain for a small company.
Recent Initiatives: Recent initiatives include advancing INTASYL and PH-762 through clinical trials and pre-clinical development.
Summary
Phio Pharmaceuticals is a high-risk, high-reward biotechnology company focused on developing RNAi therapeutics. Its sd-rxRNA technology offers a unique approach to gene silencing, but it faces significant challenges related to funding, clinical development, and competition. Success depends on positive clinical trial outcomes and strategic partnerships. Its small size and limited resources make it highly speculative.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports (limited)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Information might be outdated. Investing in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Phio Pharmaceuticals Corp
Exchange NASDAQ | Headquaters Marlborough, MA, United States | ||
IPO Launch date 2012-05-10 | President, CEO & Chairman Mr. Robert J. Bitterman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://phiopharma.com |
Full time employees 5 | Website https://phiopharma.com | ||
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.